Clinical Trials on Pemphigus Vulgaris (PV) in Italy

Total 22 results

argenx

Completed

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Pemphigus Vulgaris | Pemphigus Foliaceus

Germany, Hungary, Israel, Italy, Ukraine
argenx

Completed

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)

Pemphigus Vulgaris | Pemphigus Foliaceus

United States, Australia, Bulgaria, China, France, Georgia, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
argenx

Terminated

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (ADDRESS+)

Pemphigus Vulgaris | Pemphigus Foliaceus

United States, Germany, Italy, Australia, Bulgaria, China, France, Georgia, Greece, Hungary, India, Israel, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

Pemphigus Vulgaris

United States, Australia, Greece, Israel, Italy, Japan, Poland, Romania
Hoffmann-La Roche
Genentech, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Pemphigus Vulgaris

United States, Spain, Israel, Australia, France, Argentina, Canada, Turkey, Germany, Brazil, Italy, Ukraine
Universita di Verona

Completed

Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis

Psoriasis Vulgaris

Italy
Derming SRL

Completed

Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment (ANTI-ACNE)

Acne

Italy
Telios Pharma, Inc.

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

Spain, United States, France, Poland, Italy, Germany
Relife S.r.l.

Completed

Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.

Scars | Acne

Italy
Bayer

Completed

Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases

Acne Vulgaris

United Kingdom, Italy, Netherlands
Kartos Therapeutics, Inc.
Telios Pharma, Inc.

Recruiting

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Primary Myelofibrosis | Myelofibrosis | Post-PV MF | Post-ET Myelofibrosis

United States, Italy, Serbia, Poland, France, Austria, Bulgaria, Germany, Hungary, Spain
University of Siena

Active, not recruiting

Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis.

Periodontitis | Psoriasis | Psoriasis Vulgaris

Italy
Principia Biopharma, a Sanofi Company

Terminated

A Study of PRN1008 in Patients With Pemphigus

Pemphigus

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Poland, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Pierre Fabre Dermo Cosmetique

Completed

Assess the Effects and the Tolerance of Cosmetic Product in the Follow-up Phase of Facial Acne for 1 Year

Acne Vulgaris

France, Italy, Poland
Pfizer

Terminated

Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne

Acne Vulgaris

Italy
Galderma R&D

Completed

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Psoriasis Vulgaris

United States, Canada, Belgium, Germany, Italy
Galderma R&D

Completed

Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris (TEAM)

Acne Vulgaris

Australia, Belgium, Brazil, France, Germany, Italy, Mexico, Poland, Sweden
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
Sierra Oncology, Inc.

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2)

Primary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)

United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
GlaxoSmithKline

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

Neoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands

Clinical Trials on Pemphigus Vulgaris (PV) in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations